Streetbeat News

KVUE

Kenvue Inc.

https://www.kenvue.com

Industry

Household & Personal Products

Kenvue Inc. operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, and other products under the Tylenol, Nicorette, and Zyrtec brands. The Skin Health and Beauty segment provides face and body care, hair care, and sun and other care products under the Neutrogena, Aveeno, and OGX brand names. The Essential Health segment offers oral and baby, women's health, and wound care products under the Listerine, Johnson's, Band-Aid, and Stayfree brands. The company was incorporated in 2022 and is headquartered in Skillman, New Jersey. Kenvue Inc. operates as a subsidiary of Johnson & Johnson.

Open

23.52

Mkt cap

46B

Volume

13M

High

24.13

P/E Ratio

43.31

52-wk high

24.13

Low

23.44

Div yield

0.03

52-wk low

17.67

Kenvue shares are trading lower following mixed Q4 results and a warning about potential challenges due to the macroeconomic environment.

Portfolio Pulse from Benzinga Newsdesk

February 08, 2024 | 12:23 pm

Kenvue projects its 2024 net sales growth to be between 1.0%-3.0% and organic growth between 2.0%-4.0%. The company anticipates an adjusted EPS of $1.10-$1.20, which is below the estimated $1.26. CFO Paul Ruh highlighted the guidance accounts for potential macroeconomic challenges and uncertainties in seasonal businesses.

Portfolio Pulse from Benzinga Newsdesk

February 08, 2024 | 12:06 pm

Kenvue reported Q4 adjusted earnings of $0.31 per share, surpassing the $0.28 estimate. However, its sales of $3.67B fell short of the $3.78B estimate.

Portfolio Pulse from Benzinga Newsdesk

February 08, 2024 | 12:00 pm

Numerous companies are scheduled to report their quarterly earnings on February 8, 2024, with a mix of expected profits and losses across various sectors. Notable mentions include Ares Management, ArcelorMittal, and AstraZeneca among others, indicating a broad spectrum of financial health and industry performance.

Portfolio Pulse from Benzinga Insights

February 08, 2024 | 9:43 am

Kenvue Inc. (NYSE:KVUE) saw a slight increase in its stock price to $20.63, but experienced declines over the past month and year. Its P/E ratio of 35.92 is below the industry average, which could suggest undervaluation or weaker growth prospects. Investors should consider multiple factors beyond the P/E ratio when evaluating the company.

Portfolio Pulse from Benzinga Insights

January 25, 2024 | 5:15 pm

Johnson & Johnson (JNJ) is set to report Q4 earnings with a focus on dividend security post-Kenvue split, legal costs from talc litigation, and recent acquisitions. Analysts expect $2.28 EPS and $20.99 billion in revenue. JNJ's acquisition of Abiomed and Ambrx Biopharma (AMAM) strengthens its medical segments. Despite challenges, JNJ's dividend, with a 61-year growth history, seems secure. The stock closed at $161.68, with a Neutral consensus rating and a $175.75 price target.

Portfolio Pulse from Surbhi Jain

January 22, 2024 | 1:35 pm

Kenvue (NYSE:KVUE) has seen a decrease in short interest, with the short percent of float dropping 5.48% since the last report. The company has 36.70 million shares sold short, representing 18.46% of available shares for trading. The average time to cover these short positions is 2.15 days. A decrease in short interest may indicate a more bullish sentiment among investors. Kenvue's short interest is significantly higher than its peer group average of 5.66%.

Portfolio Pulse from Benzinga Insights

January 19, 2024 | 6:15 pm

Nasdaq, Inc. (NDAQ) is leading over the New York Stock Exchange in IPO listings for the fifth consecutive year, having raised $13.6 billion from IPOs in 2023 compared to NYSE's $10.4 billion. Notable Nasdaq IPOs include Arm Holdings Plc (ARM), Maplebear Inc. (CART), and Nextracker Inc. (NXT). The NYSE attracted Kenvue Inc. (KVUE), Birkenstock Holding PLC (BIRK), CAVA Group, Inc. (CAVA), and Klaviyo, Inc. (KVYO). Nasdaq's competitive listing fees and appeal to tech and global firms are seen as strengths. NDAQ shares rose 0.60% to $57.39.

Portfolio Pulse from Nabaparna Bhattacharya

December 26, 2023 | 6:55 pm

U.S. District Judge Denise Cote ruled that expert witnesses cannot testify that Kenvue Inc's Tylenol could cause autism if taken during pregnancy, halting mass tort litigation involving around 500 lawsuits. The ruling found the methodologies of the plaintiffs' experts unsound. The litigation also involved Johnson & Johnson, CVS Health Corp, Walgreens Boots Alliance Inc, and Walmart Inc, who faced allegations over generic versions of Tylenol. Health experts still recommend acetaminophen, Tylenol's active ingredient, for pregnant individuals over aspirin or ibuprofen. Kenvue shares dropped 0.98% to $21.26.

Portfolio Pulse from Vandana Singh

December 20, 2023 | 3:51 pm

Kenvue Inc. (NYSE:KVUE) stock has seen a 1.4% increase on Dec. 13, closing at $21.04 after-hours, but has dropped about 22% year-to-date. The stock's 52-week range was $17.82 to $27.80. Kenvue has maintained a dividend yield of 1.98%, with a $0.40 per share payout, totaling $383 million in dividend expenses from January to September. To earn $1,000 per month from dividends, an investment of approximately $606,061 is required, equating to 28,805 shares at the current price.

Portfolio Pulse from Shankar Iyer

December 20, 2023 | 2:30 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.